Online Inquiry
Bacterial Vaccine Development Service
Bacterial cancer vaccines are a new type of cancer immunotherapy that uses bacteria or their components to activate or enhance the body's immune response to cancer cells. Alfa Cytology is committed to providing a comprehensive one-stop bacterial cancer vaccine development service against prostate cancer.
Introduction to Bacterial Vaccine
There is growing evidence that bacteria have the ability to naturally target tumor tissue and modulate anti-tumor immune responses in the tumor environment. We can genetically engineer bacteria to efficiently release identified tumor neoantigens from prostate cancer, thereby constructing a neoantigen delivery system that precisely targets tumor tissue. The emergence of this approach provides a new way of thinking about bacteria-based precision prostate cancer vaccines.
Fig. 1
Engineering live microbial tumour neoantigen vaccines. (Redenti, A., et al. 2024)
Bacterial Vaccine Development for Prostate Cancer
Bacterial cancer vaccines hold great potential and promise for prostate cancer therapy, especially for their ability to personalize treatment and prevent recurrence, providing a new direction in cancer therapy.
Activation of Specific Immune Responses
Bacterial cancer vaccines activate the body's intrinsic and adaptive immune responses by delivering tumor neoantigens. These vaccines utilize the exogenous and immunostimulatory properties of bacteria as ideal vehicles to enhance and direct anti-tumor immune responses.
Personalized Therapy
Bacterial vaccines are personalized for each cancer patient by sequencing the cancer and using bioinformatics to identify its unique tumor neoantigens, and then engineering the bacteria to produce the identified tumor neoantigens, as well as other immunomodulatory factors.
Enhanced Safety and Immunogenicity
Engineered bacterial vaccines have enhanced safety and immunogenicity, creating a system capable of driving potent, specific anticancer T-cell immunity. These properties can effectively control or even eliminate tumor growth.
Preventing Tumor Recurrence
A bacterial cancer vaccine not only clears tumors but also prevents recurrence. Studies showed that a bacterial cancer vaccine injected into mice before tumors had formed was able to reduce subsequent tumor growth and prevent tumor recurrence in mice that had been cured.
Our Services
Extensive research has elucidated the complex interactions between bacteria and the immune system, paving the way for the development of innovative vaccine strategies. At Alfa Cytology, we have a professional team to provide one-stop bacterial cancer vaccine development service against prostate cancer for you.
Identify potential tumor neoantigens using advanced screening techniques. |
|
Provide reliable and reproducible relevant in vitro and in vivo models. |
Design, characterize and optimize bacterial vaccines against prostate tumor-specific antigens. |
Perform comprehensive efficacy and toxicity testing in relevant preclinical models. |
Workflow of Bacterial Vaccine Development
Selection of Target Antigens
The process of selection of target antigens involves identifying and selecting pathogens or tumor-associated proteins or peptides capable of eliciting a specific immune response to prevent or treat prostate cancer.
Vaccine Design
In vaccine design, a vaccine formulation is developed based on the selected antigen. This mainly includes the construction of antigens, selection of vectors, addition of adjuvants and development of delivery systems to enhance immunogenicity and protective efficacy.
In vitro and Animal Model Testing
In vitro and animal model testing process consists primarily of evaluating the safety, immunogenicity, and efficacy of a vaccine in cell culture and in animal models to determine whether the immune response it induces provides the desired protective effect.
Bacterial vaccines have become an increasingly important emerging therapy in the field of prostate cancer treatment. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
Reference
- Redenti, A., et al. Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature. 2024.
For research use only.